AU9312198A - Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer - Google Patents

Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer

Info

Publication number
AU9312198A
AU9312198A AU93121/98A AU9312198A AU9312198A AU 9312198 A AU9312198 A AU 9312198A AU 93121/98 A AU93121/98 A AU 93121/98A AU 9312198 A AU9312198 A AU 9312198A AU 9312198 A AU9312198 A AU 9312198A
Authority
AU
Australia
Prior art keywords
tumours
diagnosis
cancer
treatment
antibodies against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU93121/98A
Inventor
David Botstein
Audrey Goddard
Austin Gurney
Kenneth Hillan
David A. Lawrence
Margaret Roy
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU9312198A publication Critical patent/AU9312198A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU93121/98A 1997-09-17 1998-09-10 Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer Abandoned AU9312198A (en)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US5911497P 1997-09-17 1997-09-17
US5911797P 1997-09-17 1997-09-17
US60059117 1997-09-17
US60059114 1997-09-17
US5926397P 1997-09-18 1997-09-18
US60059263 1997-09-18
US6212597P 1997-10-15 1997-10-15
US60062125 1997-10-15
US6228597P 1997-10-17 1997-10-17
US6228797P 1997-10-17 1997-10-17
US60062287 1997-10-17
US60062285 1997-10-17
US6281697P 1997-10-24 1997-10-24
US60062816 1997-10-24
US6370497P 1997-10-29 1997-10-29
US60063704 1997-10-29
US6684097P 1997-11-25 1997-11-25
US60066840 1997-11-25
PCT/US1998/018824 WO1999014327A2 (en) 1997-09-17 1998-09-10 Genes amplified in tumours, antibodies against the proteins coded thereby, and their use in diagnosis and treatment of cancer

Publications (1)

Publication Number Publication Date
AU9312198A true AU9312198A (en) 1999-04-05

Family

ID=27578244

Family Applications (1)

Application Number Title Priority Date Filing Date
AU93121/98A Abandoned AU9312198A (en) 1997-09-17 1998-09-10 Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer

Country Status (2)

Country Link
AU (1) AU9312198A (en)
WO (1) WO1999014327A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004311A1 (en) * 1999-07-07 2001-01-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2001019987A1 (en) * 1999-09-13 2001-03-22 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US5728546A (en) 1995-06-05 1998-03-17 Human Genome Sciences, Inc. Fibroblast growth factor 13
US20040132987A1 (en) 1996-11-08 2004-07-08 Human Genome Sciences, Inc. Connective tissue growth factor-3
JP2001505426A (en) 1996-11-27 2001-04-24 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド Fibroblast growth factor 13
WO1999021999A2 (en) 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 inducible genes
US7169906B2 (en) 1997-09-17 2007-01-30 Genentech, Inc. PRO211 polypeptides
US20030044839A1 (en) 1997-09-17 2003-03-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6974689B1 (en) 1997-09-18 2005-12-13 Genentech, Inc. Nucleic acid encoding PRO211 polypeptides
ES2313756T3 (en) 1997-10-29 2009-03-01 Genentech, Inc. USES OF WISP-1 SECRETED POLYPEPTIDE INDUCED BY WNT-1.
NZ504425A (en) * 1997-11-25 2001-10-26 Genentech Inc Nucleic acid molecules and polypeptides of fibroblast growth factor-19 (PRO533)
EP1109833A2 (en) * 1998-09-10 2001-06-27 Genentech, Inc. Compositions and methods for the treatment of tumors
IL141537A0 (en) * 1998-09-14 2002-03-10 Genentech Inc Promotion or inhibition of angiogenesis and cardiovascularization
WO2000017236A2 (en) * 1998-09-24 2000-03-30 Millennium Pharmaceuticals, Inc. Apoptosis related protein and uses therefor
AU758462B2 (en) * 1998-10-13 2003-03-20 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
AU1749800A (en) * 1999-03-12 2000-10-04 Genentech Inc. Methods and compositions for inhibiting neoplastic cell growth
ES2287020T3 (en) * 1999-06-02 2007-12-16 Genentech, Inc. PROCEDURE AND COMPOSITIONS TO INHIBIT THE GROWTH OF NEOPLASSIC CELLS.
EP1683811B1 (en) * 1999-06-09 2009-08-19 Genentech, Inc. Methods for the diagnosis of tumors
US20030082586A1 (en) 1999-06-29 2003-05-01 Millennium Pharmaceuticals, Inc. Antibodies having diagnostic, preventive, therapeutic, and other uses
AU2390700A (en) * 1999-07-20 2001-02-05 Genentech Inc. Polypeptidic compositions and methods for the treatment of tumors
ATE326532T1 (en) * 1999-09-08 2006-06-15 Genentech Inc FIBROBLAST GROWTH FACTOR-19 (FGF-19) NUCLEIC ACID AND POLYPEPTIDES AND METHOD OF USE THEREOF FOR TREATING OBESITY
ES2264929T3 (en) * 1999-09-08 2007-02-01 Genentech, Inc. NUCLEIC AND POLYPEPTIDE ACIDS OF FIBROBLASTIC GROWTH FACTOR 19 (FGF-19) AND PROCEDURES OF USE FOR THE TREATMENT OF OBESITY.
AU7452300A (en) * 1999-10-01 2001-05-10 Kyowa Hakko Kogyo Co. Ltd. Shear stress-response dna
EP1661996A1 (en) * 1999-12-01 2006-05-31 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2003002765A2 (en) 2001-06-27 2003-01-09 Cancer Research Technology Limited Methods for the diagnosis of cancer based on the obcam and ntm genes
US7705195B2 (en) 2002-06-07 2010-04-27 Genentech, Inc. Screening method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5411860A (en) * 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
JP3399948B2 (en) * 1992-06-26 2003-04-28 ザ トラスティーズ オブ プリンストン ユニバーシティ Method for detecting precancerous cells or cancer cells using P90 antibody or probe
US5595590A (en) * 1995-05-31 1997-01-21 Nocopi Technologies, Inc. Method and compositions for authenticating a product or document
JPH11507504A (en) * 1995-06-05 1999-07-06 ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド Fibroblast growth factor 13

Also Published As

Publication number Publication date
WO1999014327A2 (en) 1999-03-25
WO1999014327A3 (en) 1999-09-30

Similar Documents

Publication Publication Date Title
AU9312198A (en) Genes amplified in tumours, antibodies against the proteins encoded thereby, andtheir use in diagnosis and treatment of cancer
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
HUP0201757A3 (en) Compositoins and methods for the therapy and diagnosis of lung cancer
AU2002308348A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours
MXPA03008739A (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours.
AU2990695A (en) Mucin-derived proteins for the diagnosis, imaging, and therapy of human cancer
WO1999033998A3 (en) Regulatory dna sequences of the human catalytic telomerase sub-unit gene, diagnostic and therapeutic use thereof
AU2001240909A1 (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU6502199A (en) Expression analysis of specific nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
AU6583700A (en) Proteins, genes and their use for diagnosis and treatment of breast cancer
AU7058000A (en) 13 human colon and colon cancer associated proteins
ZA982136B (en) Novel carboxylic acid derivatives, their preparation and use in treating cancer.
EP0666313A3 (en) Targeting of telomerase in cancer gene therapy.
AU1138699A (en) Dna demethylase, therapeutic and diagnostic uses thereof
AU1991901A (en) Pharmaceutical composition for treating and preventing human tumors, which express the tumor antigen mucin and/or the carcinoembryonic antigen (cea), and the use thereof
AU6653698A (en) Use of the p-ten suppressor gene in diagnosis and treatment of cancer
AU1774299A (en) Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
AU2003245858A1 (en) Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases
AU2002346049A1 (en) Coactivators in the diagnosis and treatment of breast cancer
AU5618700A (en) Extracellular camp-dependent protein kinase in diagnosis, prognosis and treatment of cancer
AU2003265023A1 (en) Dna-targeted benzotriazine 1,4-dioxides and their use in cancer therapy
AU1926699A (en) Cathepsin dc proteins, dna encoding the proteins, and their use in human cancer prognosis
AU2002218977A1 (en) Novel marker for the diagnosis and therapy of tumours
AU3262697A (en) Combinations comprising vx478, zidovudine and/or 1592u89 for use in the treatment of hiv
AU2002254524A1 (en) Use of semenogelin in the diagnosis, prognosis and treatment of cancer

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase